Last updated on March 2018

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Claustrophobia
  • Age: Between 18 - 64 Years
  • Gender: Male or Female
  • Other:
    Must have a primary DSM-5 diagnosis of Social anxiety disorder (SAD) except those with
    performance only as a specifier. Participants with a diagnosis of comorbid Generalized
    Anxiety Disorder (GAD) or Major Depressive Disorder (MDD) may be included if the
    Investigator considers SAD to be the predominant diagnosis. Participants with current
    or lifetime history of Attention deficit hyperactivity disorder (ADHD) and specific
    phobia may be included as well
    Must have a Liebowitz Social Anxiety Scale score greater than or equal (>=) 70 at
    Screening and Baseline
    Participants with a current episode of MDD must have a HDRS17 total score less than or
    equal to (<=) 18
    Must have a body mass index (BMI) between 18 and 35 kilogram per meter square
    (kg/m^2), inclusive, at screening
    Female participants must be either postmenopausal or surgically sterile

You may not be eligible for this study if the following are true:

  • Participants who have performance only SAD are excluded. Participants with other
    current significant psychiatric condition(s) (Axis 1 under DSM-IV), including, but not
    limited to, MDD with psychotic features (lifetime), bipolar disorder (including
    lifetime diagnosis), obsessive-compulsive disorder, borderline personality disorder,
    eating disorder (e.g., bulimia, anorexia nervosa), autism spectrum disorders,
    post-traumatic stress disorder (PTSD) or schizophrenia are excluded. Participants with
    a diagnosis of comorbid GAD or MDD may be included
    Participants is currently receiving specific psychotherapy for SAD
    Has a history of more than two unsuccessful adequate pharmacological treatment trials
    for SAD, defined as lack of response to at least 10 weeks of treatment at adequate
    doses (e.g., paroxetine >= 40 milligram per day (mg/day) or its equivalent; or
    clonazepam >= 2.5 mg/day or its equivalent)
    Concurrent use of psychotropic medications
    has a history of or current thyroid disease, thyroid dysfunction and is currently
    untreated for it

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.